Editorial Comment to Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan

被引：0
|
作者：
Kondo, Tsunenori [1 ]
机构：
[1] Tokyo Womens Med Univ, Adachi Med Ctr, Dept Urol, Tokyo, Japan
来源：
INTERNATIONAL JOURNAL OF UROLOGY | 2023年 / 30卷 / 09期
关键词：
D O I：
10.1111/iju.15256
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：777 / 778
页数：2
相关论文
共 50 条
  • [41] Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma
    Brian I. Rini
    Victor Gruenwald
    Eric Jonasch
    Mayer N. Fishman
    Yoshihiko Tomita
    M. Dror Michaelson
    Jamal Tarazi
    Laura Cisar
    Subramanian Hariharan
    Angel H. Bair
    Brad Rosbrook
    Thomas E. Hutson
    Targeted Oncology, 2017, 12 : 333 - 340
  • [42] Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma
    Rini, Brian I.
    Gruenwald, Victor
    Jonasch, Eric
    Fishman, Mayer N.
    Tomita, Yoshihiko
    Michaelson, M. Dror
    Tarazi, Jamal
    Cisar, Laura
    Hariharan, Subramanian
    Bair, Angel H.
    Rosbrook, Brad
    Hutson, Thomas E.
    TARGETED ONCOLOGY, 2017, 12 (03) : 333 - 340
  • [43] Breaking boundaries: Exploring extended pembrolizumab in first-line treatment of renal cell carcinoma with axitinib-pembrolizumab combination.
    Aydogdu, Can
    Paffenholz, Pia
    Stelmach, Ramona
    Schlack, Katrin
    Roghmann, Florian
    Handke, Analena
    Mandal, Subhajit
    Schnabel, Marco
    Merseburger, Axel
    Ivanyi, Philipp
    Zschaebitz, Stefanie
    Darr, Christopher
    Gruenwald, Viktor
    Stief, Christian G.
    Casuscelli, Jozefina
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 436 - 436
  • [44] Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma
    Gunnarsson, Orvar
    Pfanzelter, Nicklas R.
    Cohen, Roger B.
    Keefe, Stephen M.
    CANCER MANAGEMENT AND RESEARCH, 2015, 7 : 65 - 73
  • [45] Real-world experience with a first-line niraparib maintenance monotherapy for advanced ovarian carcinoma
    Gregoric, Brigita
    Skof, Erik
    Skrbinc, Breda
    Geltar, Ana
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A220 - A220
  • [46] Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in Japan
    Miyake, Hideaki
    Harada, Ken-ichi
    Ozono, Seiichiro
    Fujisawa, Masato
    CLINICAL GENITOURINARY CANCER, 2017, 15 (01) : 122 - 128
  • [47] Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results
    Atkins, M. B.
    Plimack, E. R.
    Puzanov, I.
    Fishman, M. N.
    McDermott, D.
    Cho, D. C.
    Vaishampayan, U.
    George, S.
    Olencki, T.
    Tarazi, J.
    Rosbrook, B.
    Fernandez, K.
    Keefe, S.
    Choueiri, T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [48] ASSESSMENT OF EFFICACY, SAFETY AND QUALITY OF LIFE OF 110 PATIENTS TREATED WITH SUNITINIB AS FIRST-LINE THERAPY FOR METASTATIC RENAL CELL CARCINOMA: EXPERIENCE IN REAL WORLD CLINICAL PRACTICE IN JAPAN
    Harada, Ken-ichi
    Miyake, Hideaki
    Fujisawa, Masato
    JOURNAL OF UROLOGY, 2015, 193 (04): : E870 - E870
  • [49] Efficacy and Safety of Pembrolizumab plus Axitinib combination for Metastatic Renal Cell Carcinoma in a Real-World Scenario: Data From the Prospective ProPAXI Study
    Guida, Annalisa
    Gili, Alessio
    Mosillo, Claudia
    Maruzzo, Marco
    Lai, Eleonora
    Pierantoni, Francesco
    Bimbatti, Davide
    Basso, Umberto
    Fornarini, Giuseppe
    Rebuzzi, Sara Elena
    Calabro, Fabio
    Cerbone, Linda
    Caserta, Claudia
    Sirgiovanni, Grazia
    Serafin, Debora
    Caffo, Orazio
    Scagliarini, Sarah
    Bracarda, Sergio
    CLINICAL GENITOURINARY CANCER, 2024, 22 (06)
  • [50] FIRST-LINE COMBINATION THERAPIES FOR ADVANCED RENAL CELL CARCINOMA (ARCC): AN ITALIAN SINGLE-CENTRE REAL-WORLD CLINICAL EXPERIENCE
    Mercinelli, Chiara
    Massaro, Giulia
    Bonato, Adele
    Nuzzo, Amedeo
    Manacorda, Simona
    Sammarco, Enrico
    Manfredi, Fiorella
    Ferrari, Marco
    Salfi, Alessia
    Serafin, Debora
    Zatteri, Luca
    Antonuzzo, Andrea
    Galli, Luca
    ANTICANCER RESEARCH, 2022, 42 (10) : 5144 - 5145
12345